Background
Limited empirical investigation exists into longitudinal changes in cognition, behavior, or quality of life (QOL) in children with perinatal HIV who are prescribed stimulants.
Methods
This study was an analysis of longitudinal data from children age 3-19 years, with perinatal HIV infection, with and without prescriptions for stimulant medications (prescription [PG] and comparison [CG] groups, respectively), matched on age, availability of CD4%, and outcome measures of cognition, behavior, and QOL. Generalized estimating equation models were used to evaluate effects of stimulant exposure on change in measured outcomes over three years of follow-up, adjusting for baseline levels of outcomes and relevant covariates.
Results
Children in both the PG (n=132) and CG (n=392) obtained mean Verbal and Performance (nonverbal) Intelligence Quotients (VIQ and PIQ, respectively) in the low-average range for age. At baseline, those in PG demonstrated more frequent signs of hyperactivity, impulsivity, and conduct and learning problems than those in CG (p≤0.003 in unadjusted analyses). At follow-up, after adjustment for baseline functioning and other relevant covariates, there were no significant changes from baseline in VIQ or PIQ. Stimulant prescription use, however, was associated with worsening symptoms of hyperactivity (p=0.01), impulsivity (p=0.04), and learning problems (p<0.001) and worsening of perceived health status (p<0.001).
Conclusions
The results suggest expectations for behavioral improvement may not align well with long-term effects of stimulant prescription use on behavior and QOL in children with HIV. Further research is necessary to determine if there are subsets of children who may benefit from stimulant therapy.